# Anumana

> Anumana develops AI medical software that analyzes routine ECGs to help clinicians identify patients who may need further evaluation for cardiovascular disease. Founded in 2021 by nference and Mayo Clinic, it sells to healthcare organizations and works with device and pharmaceutical partners; its portfolio also extends into cardiac procedure planning.

- **Founded:** 2021
- **Headquarters:** Cambridge, United States
- **Founders:** nference (Co-founding company; AI and data science partner), Mayo Clinic (Co-founding institution; clinical research partner), Murali Aravamudan (Co-founder and founding CEO; now Executive Chairman)
- **Products:** ECG-AI LEF, ECG-AI PH, ECG-AI CA, WatchMate Software, ECG-AI integration platform
- **Notable:** First ECG-AI LEF FDA clearance announced October 2, 2023; updated clearance K250652 dated July 28, 2025., Investigational predecessor evaluated in the 22,641-adult EAGLE randomized trial; new low-EF diagnoses were 2.1% with AI support versus 1.6% with usual care., ECG-AI LEF Medicare outpatient reimbursement pathway effective January 2025, according to the company’s CMS announcement.

## Products & services

- **ECG-AI LEF** — Prescription software that analyzes a routine 12-lead ECG to aid detection of left ventricular ejection fraction of 40% or less in adults at risk for heart failure; first FDA clearance announced October 2023, with an updated clearance in July 2025.
- **ECG-AI PH** — FDA-cleared ECG-based software supporting identification of pulmonary hypertension in the indicated adult population; clearance announced March 28, 2026.
- **ECG-AI CA** — FDA-cleared software using a standard 12-lead ECG to help identify cardiac amyloidosis risk; clearance announced April 8, 2026.
- **WatchMate Software** — FDA-cleared software for visualization and measurement of cardiac structures for left atrial appendage closure planning and sizing, using transesophageal echocardiography images. Clearance dated June 15, 2026; commercial deployment scale is not established here.
- **ECG-AI integration platform** — On-premises processing and integration with compatible ECG management systems and electronic health records, including the Philips ECG-AI Marketplace.
- **Electrophysiology and perioperative AI development** — Research and development of imaging, visualization and procedural support tools; includes capabilities acquired with NeuTrace and collaboration with Boston Scientific. Individual development programs should not be assumed cleared.

## Achievements

- First ECG-AI LEF FDA clearance announced October 2, 2023; updated clearance K250652 dated July 28, 2025.
- Investigational predecessor evaluated in the 22,641-adult EAGLE randomized trial; new low-EF diagnoses were 2.1% with AI support versus 1.6% with usual care.
- ECG-AI LEF Medicare outpatient reimbursement pathway effective January 2025, according to the company’s CMS announcement.
- FDA clearance announcements for pulmonary hypertension and cardiac amyloidosis ECG algorithms in March and April 2026.
- FDA WatchMate Software clearance dated June 15, 2026.
- Named to Fast Company’s 2026 Most Innovative Companies list, according to the company’s March 24 announcement.

## Latest updates

- **2026-06** — FDA cleared WatchMate Software on June 15 for left atrial appendage closure planning and sizing.
- **2026-04** — Anumana announced FDA clearance of its cardiac amyloidosis ECG algorithm on April 8.
- **2026-03** — Anumana announced FDA clearance of its pulmonary hypertension ECG algorithm on March 28.
- **2026-03** — Company announced inclusion in Fast Company’s 2026 Most Innovative Companies awards on March 24.
- **2026-01** — Anumana announced board appointments of Kevin Ballinger and Jean-Luc Butel on January 12.

## Links

- Website: https://anumana.ai/
- LinkedIn: https://www.linkedin.com/company/anumana-inc
- Twitter/X: https://twitter.com/anumanainc
- YouTube: https://www.youtube.com/channel/UCZlMq0PGtuZg3hLPJaVIetA

---

Profile page: https://yespress.io/anumana
Published by YesPress — https://yespress.io
Last updated: 2026-10-15